Today, April 2, 2025, LIDDS AB (the "Company") disclosed a press release with information that the Company's board of directors has decided to cease further development of the project areas Nanodotax, Nanoimod and NOV 202.
The rules of First North Growth Market state that an issuer can be given observation status if any circumstance exists that results in a substantial uncertainty regarding the issuer or the pricing of its financial instruments.
With reference to the above, Nasdaq Stockholm AB decides that the shares in LIDDS AB (LIDDS, ISIN code SE0001958612, order book ID 101904) shall be given observation status.
For further information about this exchange notice please contact Enforcement & Investigations, telephone +46 8 405 70 50.
Nasdaq Stockholm AB
